After Today’s Significant Increase, Is AMAG Pharmaceuticals, Inc. (AMAG)’s Near-Term Analysis Positive?

February 15, 2018 - By Ivan Hodges

Investors sentiment increased to 1.44 in 2017 Q3. Its up 0.35, from 1.09 in 2017Q2. It increased, as 21 investors sold AMAG Pharmaceuticals, Inc. shares while 43 reduced holdings. 35 funds opened positions while 57 raised stakes. 39.98 million shares or 4.47% less from 41.85 million shares in 2017Q2 were reported.
Invesco Limited stated it has 0% in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Envestnet Asset holds 122 shares. Nationwide Fund Advsr holds 50,978 shares. Credit Suisse Ag owns 0% invested in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) for 50,748 shares. Texas Permanent School Fund, Texas-based fund reported 25,762 shares. The Pennsylvania-based Stevens Management Limited Partnership has invested 0.02% in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Metropolitan Life Ins Com Ny owns 24,140 shares. Schroder Inv Management Gru holds 0% or 83,945 shares. Css Ltd Liability Corp Il accumulated 4,500 shares. Prudential Financial Inc invested 0.02% of its portfolio in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Moreover, Bridgeway Capital Mngmt has 0.02% invested in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Bnp Paribas Arbitrage invested in 0% or 81,231 shares. Ironwood Investment Management Ltd Liability has invested 0.5% in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Riverhead Capital Management Lc holds 3,383 shares. Ls Inv Limited Co has 4,401 shares for 0% of their portfolio.

Since August 29, 2017, it had 0 buys, and 1 insider sale for $20,938 activity.

The stock of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) is a huge mover today! The stock increased 27.70% or $3.85 during the last trading session, reaching $17.75. About 8.95M shares traded or 968.59% up from the average. AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) has risen 3.00% since February 15, 2017 and is uptrending. It has underperformed by 13.70% the S&P500.
The move comes after 7 months positive chart setup for the $627.89 million company. It was reported on Feb, 15 by We have $18.28 PT which if reached, will make NASDAQ:AMAG worth $18.84 million more.

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Ratings Coverage

Among 14 analysts covering AMAG Pharmaceuticals (NASDAQ:AMAG), 4 have Buy rating, 1 Sell and 9 Hold. Therefore 29% are positive. AMAG Pharmaceuticals had 38 analyst reports since August 18, 2015 according to SRatingsIntel. Barclays Capital initiated the stock with “Equal-Weight” rating in Thursday, January 21 report. The stock has “Hold” rating by Deutsche Bank on Wednesday, November 4. The stock of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) has “Buy” rating given on Thursday, February 15 by Janney Capital. The rating was maintained by Jefferies with “Buy” on Tuesday, June 6. The firm has “Hold” rating given on Thursday, January 18 by Piper Jaffray. The firm earned “Buy” rating on Wednesday, August 16 by Jefferies. As per Thursday, September 3, the company rating was reinitiated by Deutsche Bank. The stock has “Hold” rating by Cantor Fitzgerald on Thursday, November 2. The rating was maintained by Morgan Stanley on Friday, November 3 with “Overweight”. Raymond James downgraded AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) on Wednesday, May 4 to “Market Perform” rating.

More notable recent AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) news were published by: which released: “AMAG Pharmaceuticals Announces FDA Approval of Supplemental New Drug …” on February 05, 2018, also with their article: “AMAG Pharmaceuticals Could Be February’s Breakout Biopharma Stock” published on January 30, 2018, published: “Your Daily Pharma Scoop: AMAG Gets Label Expansion For Feraheme, Bristol-Myers …” on February 06, 2018. More interesting news about AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) were released by: and their article: “Antares Pharma, Amag Pharma shares soar premarket after FDA approves auto injector” published on February 15, 2018 as well as‘s news article titled: “Commit To Purchase AMAG Pharmaceuticals At $12, Earn 43.9% Annualized Using …” with publication date: January 23, 2018.

AMAG Pharmaceuticals, Inc., a biopharmaceutical company, makes, develops, and commercializes therapeutics for womenÂ’s health, anemia management, and cancer supportive care in the United States. The company has market cap of $627.89 million. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme , an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients with chronic kidney disease; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. It currently has negative earnings. The firm also offers Cord Blood Registry services that are related to the collection, processing, and storage of umbilical cord blood and cord tissue units for pregnant women and their families.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.